Market Newsdesk

WENZHOU, July 05, 2023 (GLOBE NEWSWIRE) — Huadi International Group Co., Ltd. (“HUDI” or the “Company”) (NASDAQ: HUDI), a leading developer and manufacturer of industrial stainless steel seamless pipes and tubes products in China, today announced that Huadi (Songyang) Co., Ltd. (“Huadi Songyang”), a wholly-owned subsidiary of the Company, has entered into an investment agreement (the “Agreement”) with Songyang County Economic Development and Investment Group Co., Ltd. (“Songyang Group”), a Songyang County local government owned enterprise in Zhejiang Province. The Agreement aims to start an advanced “Future Factory” construction project in the Chishou Industrial Zone of southwestern Zhejiang Province, China.

Puruant to the Agreement, the factory will occupy approximately 50 acres with a total investment of approximately RMB1 billion, including fixed asset investments of over RMB620 million. HUDI plans to finance the project primarily via its working capital. Huadi Songyang has officially obtained the rights to use the first portion of 26 acres of land from Songyang Economic Development Zone on June 30, 2023, for the construction of the Future Factory project.

The Future Factory project, equipped with digital production line facilities, is expected to produce 60,000 tons of stainless steel seamless tubes and special alloy steel products annually, including 300 series, 400 series, 600 series, and 800 series. The project will be constructed in two phases, with the first phase building the factory over approximately 26 acres which will commence from December 1, 2023 to November 30, 2026, and the second phase, building the factory over approximately 24 acres which will be completed within 36 months after the land meets the construction requirements.

Pursuant to the Agreement, the Songyang County local government has authorized Songyang Group to provide a series of supportive policies for the construction of the Future Factory project, including a total of RMB 15 million in infrastructure construction subsidies to be granted to Huadi Songyang upon completion of all fixed asset investments within the agreed period. Additionally, Huadi Songyang will enjoy infrastructure construction subsidies after meeting tax requirements for eight years following the factory’s completion. Other benefits include equipment investment incentives, rewards for obtaining the intelligent manufacturing title, rewards for utilizing foreign investment effectively, and incentives for attracting top managerial talents.

Mr. Wang Di, Chairman of the Company, commented, “We are pleased to have reached this important cooperation agreement with the Songyang government to launch our new factory project. With the steady growth in market demand, we expect continuous increase in product orders. Therefore, expansion of production capacity and digital transformation of our production line are our key strategic plans in the coming years.”

“In addition, the strong support of Songyang County government’s investment attractions policies is one of the main reasons why we chose to locate our new factory in Songyang County, Zhejiang Province. The Future Factory project will enable us to continuously expand our production capacity of high-quality products while maintaining high-cost efficiency to meet the most stringent industry standards and provide excellent products to our customers. After completion of the project, we expect the project will be able to bring an annual output value of approximately RMB1.7 billion to HUDI. We will also focus on building a smart factory and digital management of manufacturing. We look forward to the significant economic boost and increased job opportunities that the construction of the new factory will bring to Songyang County.”

About
Huadi
International Group Co., Ltd.

Huadi International Group Co., Ltd. is a leading manufacturer of industrial stainless steel seamless pipes and tubes products with extensive distribution facilities and network for over twenty provinces in China and across international steel pipes industry. It offers a broad range of products exported to twenty countries and regions such as United States, Mexico, Thailand, Australia, Argentina, Taiwan, India, the Philippines, UAE and Canada. Its products are widely used in the oil & gas transmission, chemistry engineering, food processing, medical devices, aeronautics and astronautics, boiler, irrigation works construction, electricity, automobile, naval architecture, paper mill and mechanical industries. For more information about the Company, please visit: http://www.huadi.cc.

Forward-Looking Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s goals and strategies; the Company’s future business development; financial condition and results of operations; product and service demand and acceptance; reputation and brand; the impact of competition and pricing; changes in technology; government regulations; fluctuations in general economic and business conditions in China and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward‐looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

The Company:

IR Department
Email: [email protected]

Investor Relations:

Wealth Financial Services LLC
Janice Wang
Email: [email protected]
Phone: +86 13811768599
+1 628 283 9214

MINNEAPOLIS, July 05, 2023 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the second quarter 2023 after the close of trading on Tuesday, August 1. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire’s Q2 2023 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Inspire’s Q2 2023 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call. 

Following the call, a replay will be available on the Company’s Investor Relations website approximately two hours after the event and archived on the site for two weeks.

About Inspire Medical Systems

Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact

Ezgi Yagci
Vice President, Investor Relations
[email protected]
617-549-2443

NEW YORK and LONDON, July 05, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of industry veteran Wa’el Hashad to the Akari Board of Directors as an independent director. Mr. Hashad, who will serve on both the Audit Committee and Nominating and Governance Committee, brings more than 35 years of biopharmaceutical experience to Akari’s Board of Directors with focus on drug approval and commercialization, mergers and acquisitions, and business development.

“I am pleased to welcome Wa’el to our Board of Directors” said Ray Prudo, M.D., Akari Chairman. “His extensive experience in biopharma development will be invaluable as we advance nomacopan into the registrational portion of Phase 3 studies in pediatric and adult HSCT-TMA and toward clinical trials of PAS-nomacopan in geographic atrophy. His appointment strengthens the Board’s biotech and U.S. capabilities.”

“This is an exciting time for the company, and I look forward to partnering with Board members and management to advance the company’s lead asset toward a potential regulatory filing,” said Mr. Hashad.

Mr. Hashad currently serves as CEO of Longeveron, a U.S. clinical-stage biotechnology company developing regenerative medicines for rare pediatric diseases, aging-related conditions, and unmet medical needs. Previously, he was President and Chief Executive Officer at Avanir Pharmaceuticals. Avanir was acquired by Otsuka Pharmaceutical, and Mr. Hashad led the company’s full integration into Otsuka’s United States operations. Prior to Avanir, Mr. Hashad was Executive Vice President and Chief Commercial Officer at Seres Therapeutics, where he established the company’s launch and marketing strategy for microbiome-based therapies.

Mr. Hashad has held multiple leadership roles at Amgen, executing on cardiovascular, neuroscience, metabolic disorder, and nephrology product launches and was the general manager for Africa, the Middle East, and Asia. He was a Vice President at Boehringer Ingelheim leading the U.S. launch of the company’s cardiovascular and metabolic products. Earlier, Mr. Hashad spent 20 years at Eli Lilly and Company, driving the company’s marketing and commercial strategy across multiple regions and therapeutic areas. He concluded his time at Eli Lilly as the Vice President of the United States Cardiovascular Business Unit.

Mr. Hashad holds an M.B.A. in Finance and International Business from the University of Akron and a B.Sc. in Pharmacy and Pharmaceutical Sciences from the University of Cairo. He held the position of the Chairman of the Strategic Advisory Board at Morningside Biopharma and is currently a member of the Board of California Life Sciences.

About Akari Therapeutics

Akari Therapeutics, plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari’s lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Akari’s pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). Akari has been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the FDA for nomacopan for the treatment of pediatric HSCT-TMA. Akari’s pipeline also includes a clinical program developing nomacopan for adult HSCT-TMA and pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). For more information about Akari, please visit akaritx.com.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies, and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Such risks and uncertainties for our company include, but are not limited to: needs for additional capital to fund our operations, our ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; an inability or delay in obtaining required regulatory approvals for nomacopan and any other product candidates, which may result in unexpected cost expenditures; our ability to obtain orphan drug designation in additional indications; risks inherent in drug development in general; uncertainties in obtaining successful clinical results for nomacopan and any other product candidates and unexpected costs that may result there; difficulties enrolling patients in our clinical trials; failure to realize any value of nomacopan and any other product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing product candidates; the approval by the FDA and EMA and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for nomacopan may not be as large as expected risks associated with the impact of the COVID-19 pandemic; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing capabilities; the inability to timely source adequate supply of our active pharmaceutical ingredients from third party manufacturers on whom the company depends; unexpected cost increases and pricing pressures and risks and other risk factors detailed in our public filings with the U.S. Securities and Exchange Commission, including our most recently filed Annual Report on Form 20-F filed with the SEC. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.

For more information

Investor Contact:
Mike Moyer
LifeSci Advisors
(617) 308-4306
[email protected]

Media Contact:
Eliza Schleifstein
Schleifstein PR 
(917) 763-8106
[email protected]

MONACO, July 05, 2023 (GLOBE NEWSWIRE) — Costamare Inc. (the “Company”, “Costamare”) (NYSE: CMRE) has appointed Peter Lund as Chief Commercial Officer. He is expected to take up his position with Costamare in October 2023.

Mr. Lund is currently Vice President, Head of Chartering of A.P. Moller-Maersk in Copenhagen, and has worked for a total of 24 years in the A.P. Moller group of companies in different geographic locations.

Konstantinos Konstantakopoulos, Chairman and Chief Executive Officer of Costamare, commented: “We are very pleased to welcome back Mr. Lund as the new Chief Commercial Officer of our company. His broad international shipping background and detailed knowledge of several of our target segments will be very valuable for us as we continue our profitable growth and diversification.” 

About Costamare Inc.

Costamare Inc. is one of the world’s leading owners and providers of containerships and dry bulk vessels for charter. The Company has 49 years of history in the international shipping industry and a fleet of 71 containerships, with a total capacity of approximately 524,000 TEU and 43 dry bulk vessels with a total capacity of approximately 2,369,000 DWT (including one vessel that we have agreed to sell). The Company also has a dry bulk operating platform which charters in/out dry bulk vessels, enters into contracts of affreightment, forward freight agreements and may also utilize hedging solutions. The Company participates in a leasing business that provides financing to third party owners. The Company’s common stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock trade on the New York Stock Exchange under the symbols “CMRE”, “CMRE PR B”, “CMRE PR C”, “CMRE PR D” and “CMRE PR E”, respectively.

Forward-Looking Statements

This press release contains “forward-looking statements”. In some cases, you can identify these statements by forward-looking words such as “believe”, “intend”, “anticipate”, “estimate”, “project”, “forecast”, “plan”, “potential”, “may”, “should”, “could” and “expect” and similar expressions. These statements are not historical facts but instead represent only the Company’s belief regarding future results, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that actual results may differ, possibly materially, from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in the Company’s Annual Report on Form 20-F (File No. 001-34934) under the caption “Risk Factors”.

Company Contacts:

Gregory Zikos – Chief Financial Officer
Konstantinos Tsakalidis – Business Development, Investor Relations

Costamare Inc., Monaco
Tel: (+377) 93 25 09 40
Email: [email protected]

SHORT HILLS, New Jersey and ATLANTA, July 05, 2023 (GLOBE NEWSWIRE) — Avina Clean Hydrogen Inc. (“Avina”), a leading developer of electrolytic hydrogen plants, is proud to announce a partnership agreement with Chart Industries, Inc. (“Chart”, NYSE: GTLS), a global leader in design and manufacture of equipment for the entire hydrogen supply chain. Under the terms of the agreement, Chart will supply their Howden compressors for Avina’s state-of-the-art green hydrogen facility in Southern California (USA). The gaseous hydrogen will be compressed and used to decarbonize heavy-duty trucks, marking a significant milestone as the region’s first green hydrogen plant. Chart’s Howden diaphragm “D” series compressors will enable the safe and efficient transportation of compressed gaseous hydrogen, ensuring its availability as a clean fuel source for heavy-duty trucks throughout Southern California.

The partnership’s efforts will drive the expansion of sustainable transportation infrastructure and establish Southern California as a leader in green hydrogen. “Avina is proud to work with Chart on this first-of-its-kind green hydrogen project in Southern California, deepening our partnership,” said Vishal Shah, founder and CEO, Avina Clean Hydrogen Inc. “Chart’s Howden compressors are best in class, ensuring the reliability and high quality of Avina’s green hydrogen for commercial mobility and other markets in California.”

Jill Evanko, President and CEO of Chart said “Our partnership with Avina showcases Chart’s expertise in designing and delivering cutting-edge hydrogen solutions across the entire hydrogen value chain. With a rich history of over 100 years in hydrogen compression leadership, our solution for this project focuses on ensuring the safety and efficiency of hydrogen compression, while providing ongoing support to optimize plant performance and reliability. This project is another testament to Chart’s expertise in developing and delivering innovative yet cost-effective hydrogen technologies.”

For more information about Avina Clean Hydrogen Inc. and Chart Industries Inc., please visit their respective websites at www.avinah2.com and www.chartindustries.com.

About Avina Clean Hydrogen Inc.

Avina is a pioneer in the green hydrogen and green fuels sector with the most advanced portfolio of clean hydrogen plants under development and access to proprietary technology solutions. Avina uses a technology enabled production approach to make distributed green hydrogen cheaper than grey hydrogen today. Avina’s team has unparalleled expertise in the green hydrogen sector and is developing proprietary solutions to integrate intermittent renewable power with commercially available hydrogen technologies. Avina has 1.5 GW of clean hydrogen plants planned or under development with some of the largest corporations in the world.

About Chart Industries Inc.

Chart Industries, Inc. is an independent global leader in the design, engineering, and manufacturing of process technologies and equipment for gas and liquid molecule handing for the Nexus of Clean™ – clean power, clean water, clean food, and clean industrials, regardless of molecule. The company’s unique product and solution portfolio across stationary and rotating equipment is used in every phase of the liquid gas supply chain, including engineering, service and repair and from installation to preventive maintenance and digital monitoring. Chart is a leading provider of technology, equipment and services related to liquefied natural gas, hydrogen, biogas, and CO2 capture amongst other applications. Chart is committed to excellence in environmental, social and corporate governance (ESG) issues both for its company as well as its customers. With 64 global manufacturing locations and over 50 service centers from the United States to Asia, Australia, India, Europe and South America, the company maintains accountability and transparency to its team members, suppliers, customers, and communities. To learn more, visit www.chartindustries.com  

Avina Media Contact

Nihal Kerim
[email protected]

Chart Investor Relations Contact:

John Walsh
VP, Investor Relations
1-770-721-8899
[email protected]